Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-22
DOI
10.3389/fonc.2021.657639
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
- (2021) M. Kfoury et al. ESMO Open
- Radiomics: from qualitative to quantitative imaging
- (2020) William Rogers et al. BRITISH JOURNAL OF RADIOLOGY
- Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).
- (2020) Daniele Santini et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
- (2020) Takehiro Tozuka et al. BMC CANCER
- Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis
- (2020) Jun Nishida et al. NATURE CELL BIOLOGY
- Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
- (2020) Matthew Kyle Labriola et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
- (2020) Brian I. Rini et al. EUROPEAN UROLOGY
- Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
- (2020) Roberto Iacovelli et al. Targeted Oncology
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
- (2020) Laurence Albiges et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma
- (2020) Giuseppe Procopio et al. LANCET ONCOLOGY
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer
- (2020) T. Powles ANNALS OF ONCOLOGY
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Infiltration in Renal Cell Carcinoma
- (2019) Shichao Zhang et al. CANCER SCIENCE
- Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
- (2019) Solène-Florence Kammerer-Jacquet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
- (2019) Andreas Kahlmeyer et al. Journal of Clinical Medicine
- PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN
- (2019) Abdallah Flaifel et al. CLINICAL CANCER RESEARCH
- Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma
- (2019) Atsunari Kawashima et al. Clinical Genitourinary Cancer
- Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
- (2019) Bernard Escudier et al. EUROPEAN UROLOGY
- Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma
- (2019) Chuanjie Zhang et al. Annals of Translational Medicine
- Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
- (2019) Frede Donskov et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile
- (2018) Nazli Dizman et al. EUROPEAN UROLOGY
- First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
- (2018) Christopher J.D. Wallis et al. EUROPEAN UROLOGY
- Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
- (2018) Max D. Wellenstein et al. IMMUNITY
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
- (2018) Maria Giuseppa Vitale et al. PLoS One
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
- (2018) Jing Zhang et al. SCIENCE
- Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis
- (2018) Peter Hale et al. Journal of Geriatric Oncology
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Thomas Powles et al. BRITISH JOURNAL OF CANCER
- Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
- (2018) Kosuke Ueda et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
- (2018) Jiaxi Yao et al. Cancer Management and Research
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
- (2017) Sumanta K. Pal et al. EUROPEAN UROLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity in renal cell carcinoma
- (2017) Alp Tuna Beksac et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
- (2017) Andrew W. Hahn et al. Oncotarget
- Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
- (2016) Martin H Voss et al. BRITISH JOURNAL OF CANCER
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma
- (2016) M. L. Ascierto et al. Cancer Immunology Research
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
- (2016) G. de Velasco et al. Cancer Immunology Research
- Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas–Renal Cell Carcinoma (TCGA–RCC) Imaging Research Group
- (2015) Atul B. Shinagare et al. ABDOMINAL IMAGING
- Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma
- (2015) Y Chang et al. BRITISH JOURNAL OF CANCER
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype
- (2015) A Ari Hakimi et al. MODERN PATHOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- (2015) S.-J. Shin et al. ONCOLOGIST
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
- (2015) R. W. Joseph et al. Cancer Immunology Research
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
- (2014) L.B. Jilaveanu et al. Journal of Cancer
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Integrated molecular analysis of clear-cell renal cell carcinoma
- (2013) Yusuke Sato et al. NATURE GENETICS
- A clear picture of renal cell carcinoma
- (2013) A Ari Hakimi et al. NATURE GENETICS
- Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations
- (2013) Christoph A. Karlo et al. RADIOLOGY
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- Loss of p53 in Enterocytes Generates an Inflammatory Microenvironment Enabling Invasion and Lymph Node Metastasis of Carcinogen-Induced Colorectal Tumors
- (2012) Sarah Schwitalla et al. CANCER CELL
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
- (2010) P.D. Nathan et al. CANCER BIOLOGY & THERAPY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
- (2009) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
- (2009) Etienne Meylan et al. NATURE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started